Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 94 of the 94 references it cites were found in a registry or an index.

Immune modulatory effects of oncogenic KRAS in cancer

Open access

Abstract

Oncogenic KRAS mutations are the most frequent mutations in human cancer, but most difficult to target. While sustained proliferation caused by oncogenic KRAS -downstream signalling is a main driver of carcinogenesis, there is increasing evidence that it also mediates autocrine effects and crosstalk with the tumour microenvironment (TME). Here, we discuss recent reports connecting KRAS mutations with tumour-promoting inflammation and immune modulation caused by KRAS that leads to immune escape in the TME. We discuss the preclinical work on KRAS-induced inflammation and immune modulation in the context of currently ongoing clinical trials targeting cancer entities that carry KRAS mutations and strategies to overcome the oncogene-induced effects on the immune system.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-020-19288-6

Cites

94 of 94 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Pro-inflammatory effects of KRAS-induced inflammation in cancer. Pro-inflammatory effects mediated by the activation of transcription factors (STAT3), the production of cytokines (e.g., IL-6), the activation of NLRP3 inflammasome and the release of chemokines caused by oncogenic KRAS activation are listed. Representative immune cells in the tumour microenvironment (TME) affected by some of these signals are shown. The dotted line indicates co-occurring mutations.
Fig. 1 Pro-inflammatory effects of KRAS-induced inflammation in cancer. Pro-inflammatory effects mediated by the activation of transcription factors (STAT3), the production of cytokines (e.g., IL-6), the activation of NLRP3 inflammasome and the release of chemokines caused by oncogenic KRAS activation are listed. Representative immune cells in the tumour microenvironment (TME) affected by some of these signals are shown. The dotted line indicates co-occurring mutations.CC BY · PubMed Central
Fig. 2 Effects of KRAS-induced immune modulation in cancer. Multiple intracellular downstream effects of KRAS on chemokine production (CXCL3), cytokine production, MHC expression and ligand expression are shown. Mutations are indicated by a red star symbol (activating mutations in MYC, inactivating mutations in TP53 and STK11/LKB1). The dotted line indicates co-occurring mutations.
Fig. 2 Effects of KRAS-induced immune modulation in cancer. Multiple intracellular downstream effects of KRAS on chemokine production (CXCL3), cytokine production, MHC expression and ligand expression are shown. Mutations are indicated by a red star symbol (activating mutations in MYC, inactivating mutations in TP53 and STK11/LKB1). The dotted line indicates co-occurring mutations.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 94 references

Cited by

See all 387

Metadata

Authors
Hamarsheh, S., Groß, O., Brummer, T., & Zeiser, R.
Affiliations
University of Freiburg (DE)
Corresponding author
Zeiser, Robert
Venue
Nature Communications
Published
2020-10-28
Volume
11
Issue
1
Pages
5439-5439
ISSN
2041-1723 (ISSN-L)
OpenAlex
W3095726304
Cited by
387
References
94
Citations by year
2026: 50 · 2025: 78 · 2024: 80 · 2023: 66 · 2022: 61 · 2021: 50 · 2020: 2
FWCI
4.94
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Deutsche Forschungsgemeinschaft (SFB1160, SFB850, TRR167)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
  • Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
Keywords
oncogenic KRAS, KRAS mutation, tumor microenvironment, immune evasion, immunomodulation, autocrine signaling, cancer immunotherapy, KRAS-targeted therapy
MeSH terms
Animals, Humans, Inflammation, Signal Transduction, Proto-Oncogene Proteins p21(ras), Models, Immunological, Mice, Immunomodulation, Translational Research, Biomedical, Carcinogenesis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Immune modulatory effects of oncogenic KRAS in cancer. https://app.cochat.ai/papers/10.1038/s41467-020-19288-6
The paper
Hamarsheh, S., Groß, O., Brummer, T., & Zeiser, R. (2020). Immune modulatory effects of oncogenic KRAS in cancer. Nature Communications. https://doi.org/10.1038/s41467-020-19288-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.